L. Ron Hubbard’s Boys: Fellow Scientology OT8’s Grant Cardone and Bob Duggan are surrounded by lawsuits. What did they do they to pull in their legal problems?

At age 80, Scientologist billionaire Bob Duggan still surfs. However, these days he and his 1960’s-era longboard are surrounded by sharks.

Bob Duggan and his Summit Therapeutics (NASDAQ: SMMT) are simultaneously facing three distinct legal challenges that, taken together, paint a picture of a company whose legal and regulatory exposure is expanding on multiple fronts simultaneously.

• A Johnson and Johnson trade secret lawsuit filed in March 2026.
  x
• A shareholder securities fraud investigation initiated by multiple law firms, including Pomerantz LLP — the firm that won a $3 billion settlement against Petrobras — following two consecutive stock crashes totaling over 55% from peak.
  x
• A Delaware Chancery Court lawsuit alleging that Duggan and co-CEO Maky Zanganeh engineered a “plainly usurious” $520 million loan to extract $114 million from the company for themselves.

Three lawsuits. Three different legal theories. Three different sets of plaintiffs. One Scientology OT8 and his wife Dr. Maky Zanganeh are at the center of all of them.

We have been watching Bob Duggan for years. We documented his Panama Papers connections and his ties to the Shawkat money from Iraq and two companies in Hong Kong which he seems to have never talked about.

When Pomerantz first issued its investigation alert in June 2025, we noted it and observed: this is how it all began at GPB Capital. A securities law firm issues a press release. We will continue to monitor. The monitoring has produced significant new material.

I. The Three-Front Legal War: An Overview

Let us establish the three vectors before examining each in depth, because the simultaneity is itself the story.

Vector One — J&J Trade Secret Lawsuit (March 2026): Johnson and Johnson subsidiary Janssen Global Services sued a former oncology medical affairs employee — now employed at Summit Therapeutics — alleging she downloaded more than 7,000 confidential internal documents to her personal device in the months before leaving J&J in November 2025.

J&J describes Summit as a “direct competitor” in the EGFR-mutated non-small cell lung cancer space where both companies are competing. The complaint characterizes the document theft as “malicious.” J&J’s forensic review found that the employee began transferring large volumes of internal documents to her personal device a few days after receiving negative work feedback.

Vector Two — Shareholder Fraud Investigations (2025-2026): Multiple law firms, including Pomerantz LLP, Levi and Korsinsky, the Schall Law Firm, and the Portnoy Law Firm, are investigating potential securities violations related to Summit’s HARMONi Phase III clinical trial results for ivonescimab.

The first stock crash — 30.5%, or $7.99 per share, on May 30, 2025 — followed Summit’s announcement that ivonescimab failed to achieve statistically significant overall survival improvement despite showing a 48% reduction in progression or death versus chemotherapy alone.

The second crash — 25.15%, or $6.54 per share, on September 8, 2025 — followed an additional data release showing the drug produced weaker results in North American and European patients than in other geographies. Two stock crashes totaling over 55% from peak, triggered by sequential clinical trial announcements. Pomerantz has been issuing investigation alerts continuously since September 2025.

Vector Three — $520 Million Self-Dealing Loan (Delaware Chancery, March 2025): A lawsuit unsealed in Delaware’s Court of Chancery alleges that Bob Duggan forced Summit into a “plainly usurious” $520 million bridge loan connected to the Akeso partnership — a loan structured to allow Duggan and Maky Zanganeh to extract $114 million from the company. Bloomberg Law reported the complaint’s allegation that Duggan and Zanganeh exploited their control over Summit to manipulate the terms and timing of a bridge loan repayable in millions of extra shares. The complaint describes the transaction as “outlandish” self-dealing.

II. The J&J Trade Secret Lawsuit: What It Means for Ivonescimab

The Johnson and Johnson trade secret lawsuit is the most recent and in some respects the most operationally dangerous of the three legal vectors, because it strikes directly at the commercial viability of ivonescimab — the drug on which Summit’s entire enterprise value rests.

The former J&J employee at the center of the lawsuit managed Rybrevant (amivantamab) and Lazcluze (lazertinib) at Janssen — both drugs targeting EGFR-mutated non-small cell lung cancer, exactly the indication Summit is pursuing FDA approval for with ivonescimab. The FDA has accepted Summit’s Biologics License Application for ivonescimab in this indication, with a PDUFA goal date of November 14, 2026. The BLA is the regulatory event that Summit’s entire market narrative depends upon.

J&J’s forensic review found that the employee began transferring documents to her personal device shortly after receiving negative work feedback — a timeline that suggests the transfers were deliberate and motivated. The 7,000-plus documents allegedly include brand strategies and clinical trial materials directly relevant to the competitive landscape Summit is entering. J&J describes Summit as a “direct competitor” — not a peripheral player, but the primary competitive threat in the post-TKI EGFR-mutated NSCLC space.

The legal exposure for Summit is layered.

First, if it is established that a Summit employee arrived with stolen J&J competitive intelligence — brand strategies, clinical trial data, market positioning materials — the question of whether Summit used that intelligence in developing its commercial strategy becomes a live issue in the litigation.

Second, the lawsuit arrives seven months before the FDA’s PDUFA decision date on ivonescimab. J&J’s complaint now becomes part of Summit’s public legal record, available to any FDA reviewer or institutional investor conducting due diligence.

Third, J&J is not a plaintiff without resources. It is one of the largest pharmaceutical companies on earth, with litigation infrastructure that can pursue this case to any endpoint it chooses. 

Summit did not immediately respond to press inquiries about the lawsuit. Bob Duggan and Maky Zanganeh were scheduled to present at three investor conferences in March 2026 — TD Cowen, Jefferies, and Citizens Life Sciences. None of those presentations addressed the J&J complaint.

III. The Ivonescimab Data Problem: What Two Stock Crashes Tell Us

To understand the shareholder fraud investigation, you have to understand what happened to Summit’s stock on two specific dates in 2025 — and what the company had been saying to investors in the months before each crash.

Summit’s stock peaked above $33 per share in early 2025, propelled by extraordinary investor enthusiasm about ivonescimab’s prospects following Chinese clinical data showing the drug significantly outperformed Keytruda (pembrolizumab) in certain lung cancer settings. That Chinese data — from Akeso’s trials in Chinese patient populations — drove the stock to levels implying that Duggan had, as he did with Pharmacyclics, found lightning in a bottle a second time.

On May 30, 2025, Summit announced topline results from the HARMONi Phase III trial — the first global, non-China study of ivonescimab. The results were deeply ambiguous. Patients treated with ivonescimab and chemotherapy were 48% less likely to progress or die than patients receiving chemotherapy alone — a striking progression-free survival benefit. But the drug failed to achieve statistically significant improvement in overall survival, the metric that actually measures how long patients live. The stock fell 30.5% in a single session.

On September 7, 2025, Summit released additional HARMONi data showing that ivonescimab’s results in North American and European patients were notably weaker than in other geographies. The drug that had shown extraordinary efficacy in Chinese trials was performing differently in Western patient populations. The stock fell another 25.15% the following day.

The two crashes together erased more than half the stock’s peak value. The shareholder fraud investigations center on a specific question: what did Summit’s management know about the drug’s efficacy profile — particularly the geographic variation in outcomes — and what did they say to investors before those announcements?

Pomerantz LLP is not a firm that issues investigation alerts as a marketing exercise. Pomerantz won a $3 billion settlement against Petrobras in the Lava Jato case — one of the largest securities class action settlements in history. Founded by Abraham Pomerantz, the dean of the class action bar, the firm pioneered the field of securities class actions. When Pomerantz issues multiple investigation alerts over a period of months, as it has done continuously since September 2025 on Summit, it is building a case, not generating publicity. The pattern here — positive efficacy signals followed by sequential disclosure of negative data causing successive stock crashes — is exactly the fact pattern Pomerantz was built to prosecute.

Summit has filed a BLA with the FDA based on the overall HARMONi results and received a PDUFA date of November 14, 2026. The company holds approximately $713 million in cash as of December 31, 2025, and has expanded its pipeline through collaborations with GSK and Revolution Medicines. The stock was trading around $16 per share as of early March 2026 — roughly half its peak value — with 27.4% of the float sold short, representing significant bearish institutional sentiment. Short interest has increased 74.2% over the past twelve months.

The FDA decision date and the litigation timeline are now running in parallel. If the FDA approves ivonescimab in November 2026, the commercial narrative overwhelms the legal exposure. If the FDA issues a complete response letter — a rejection — the shareholder litigation becomes the dominant story, and the data that management knew before the May and September 2025 announcements becomes the evidentiary foundation for a class action.

IV. The $520 Million Self-Dealing Loan: The Duggan Pattern

The Delaware Chancery lawsuit alleges a transaction structure that will be immediately recognizable to anyone who has followed Bob Duggan’s history — and to anyone who has followed Grant Cardone’s SEC filings.

According to Bloomberg Law’s reporting on the unsealed complaint, Duggan and Maky Zanganeh used their control over Summit to engineer a $520 million bridge loan connected to the Akeso partnership — a loan structured in a way that allowed them to extract $114 million from the company personally. The complaint describes the loan as “plainly usurious” and the self-dealing as “outlandish.” An investor challenged the transaction in Delaware’s Court of Chancery, seeking corporate records to investigate whether the financing arrangement benefited the company’s co-CEOs at shareholders’ expense.

The transaction’s genesis dates to July 2024, when a shareholder first sued in Delaware seeking corporate records related to the $520 million financing arrangement connected to the Akeso partnership. The unsealed complaint in March 2025 gave the allegation public form: Duggan and Zanganeh manipulated the terms and timing of a bridge loan repayable in millions of extra shares — a structure that benefited the insiders and diluted other shareholders.

The structural parallel to Grant Cardone’s fund architecture is precise. Cardone’s self-dealing cycle — contributing $25,000 of his own money, receiving 1,000 free voting units with sole control, collecting acquisition fees, and taking 30-35% of profits while investors bear all the risk — is the retail version of the same basic design: the insider controls the terms, the insider extracts value, and the outside investors bear the dilution or the downside. The Delaware Chancery lawsuit alleges Duggan ran the institutional version of this playbook at a $520 million scale.

Bob Duggan’s net worth, built primarily from selling Pharmacyclics to AbbVie for $21 billion in 2015 — generating a personal gain of approximately $3.2 billion — gives him both the capital to engineer these structures and the credibility to attract institutional investors who trust his track record. The IAS and the Church of Scientology received 100,000 AbbVie shares from the Duggan family following the Pharmacyclics sale. The amount represented a substantial donation to David Miscavige’s entities. The Church received its cut. Now the Delaware courts are examining whether Duggan’s Summit investors received theirs.

IV-A. The Delaware Senate Bill 21 Constitutional Challenge: A Wild Card That Could Reshape Corporate Law

Rainaldi Revocable Trust v. Robert W. Duggan, Mahkam Zanganeh, Manmeet Soni, Robert Booth, and Ujwala Mahatme, C.A. No. 2025-0293-MTZ, filed May 29, 2025 in the Delaware Court of Chancery — is not merely a self-dealing lawsuit. It is a constitutional challenge to a Delaware statute that, if successful, could reshape corporate governance law for every Delaware-incorporated company in the United States.

The plaintiff, Rainaldi Revocable Trust, is asking the Delaware Court of Chancery to certify two constitutional questions to the Delaware Supreme Court.

The first question — the Jurisdiction Question — asks whether Delaware Senate Bill 21’s “Safe Harbor Provision,” codified at 8 Del. C. § 144, violates the Delaware Constitution of 1897 by eliminating the Court of Chancery’s ability to award equitable relief or damages where the Safe Harbor is satisfied. In plain terms: did the Delaware legislature unconstitutionally strip the Court of Chancery of its centuries-old equitable jurisdiction in order to immunize conflicted insider transactions from judicial remedy?

The second question — the Retroactivity Question — asks whether Section 3 of Senate Bill 21’s “Retroactivity Provision” violates the Delaware Constitution by applying retroactively to litigation that was already pending in court when the statute was passed.

To understand why these questions matter, you need to understand what Delaware Senate Bill 21 actually is and why it was passed.

SB 21 was enacted in early 2025 as the Delaware legislature’s direct response to a wave of stockholder litigation targeting controlling-shareholder transactions — precisely the category of transaction that Duggan’s $520 million bridge loan represents. SB 21 created a new safe harbor: if a conflicted transaction is approved by a special committee of independent directors or by a majority of disinterested stockholders, the Court of Chancery loses its traditional ability to award equitable relief or damages against the insiders who structured the deal.

The Rainaldi Trust is making a pointed argument: that SB 21 was passed specifically to retroactively immunize exactly the kind of self-dealing transaction Duggan and Zanganeh are accused of engineering — and that applying that statute to litigation already pending in the Delaware Court of Chancery violates the Delaware Constitution’s protections against retroactive legislation and the constitutional guarantee of the Court of Chancery’s equitable jurisdiction.

This is not a niche procedural argument. It is a direct challenge to whether the Delaware legislature can effectively pass a law protecting a specific class of defendants from specific pending lawsuits. If the Delaware Supreme Court finds either provision unconstitutional — the Safe Harbor or the Retroactivity clause — every conflicted insider transaction that SB 21 was designed to immunize potentially becomes re-exposed to the Court of Chancery’s full equitable jurisdiction. That consequence extends far beyond Summit Therapeutics to every Delaware-incorporated company whose insiders relied on SB 21’s protection for transactions already under challenge.

Summit Therapeutics, incorporated in Delaware, has become the test case.

This is a full director and officer liability case, not a two-person dispute. The fiduciary duty allegations run to Summit’s entire senior leadership structure, not merely its two co-CEOs. The depth of that penetration is captured in a single detail from Summit’s own DEF 14A proxy statement filed with the SEC: Manmeet Soni — named defendant, COO, and CFO — is the designated officer to whom shareholders must address proxy voting revocation instructions. The man responsible for Summit’s financial controls and shareholder voting machinery is a named defendant in a lawsuit alleging that Summit’s controlling shareholders used their position to extract $114 million from the company through a self-dealing loan structure.

The constitutional challenge adds a dimension to the Summit Therapeutics litigation that no financial analyst covering SMMT has fully reckoned with. The shareholder fraud investigation, the J&J trade secret lawsuit, and the self-dealing loan case are all serious matters. But a Delaware Supreme Court ruling on SB 21’s constitutionality — with Summit as the originating case — would be a landmark corporate governance decision with implications extending to thousands of Delaware-incorporated companies. Bob Duggan, OT8 Scientologist, has inadvertently placed himself at the center of what may become one of the most consequential Delaware corporate law cases in a generation.

We will be watching.

IV-B. The $520 Million Self-Dealing Structure: What Summit’s Own Proxy Discloses

The Rainaldi complaint does not rely on leaked documents or confidential sources. The self-dealing structure it challenges is disclosed in black and white in Summit Therapeutics’ own definitive proxy statement filed with the SEC on April 29, 2025. What follows is drawn directly from that filing.

In December 2022, Summit needed $520 million in bridge financing to fund its Akeso partnership. Rather than borrowing from a bank, an institutional lender, or the capital markets, Duggan and Zanganeh lent the money to their own company personally. Duggan issued two notes — a $400 million note due February 15, 2023, and a separate $100 million note due September 15, 2023. Zanganeh issued a $20 million note due February 15, 2023. The initial interest rate was 7.5%, escalating after February 15, 2023 to the U.S. prime rate plus 50 basis points for three months, and thereafter to prime plus 300 basis points — a punishing escalator on a company the lenders themselves controlled as co-CEOs and Chairman of the Board.

The prepaid interest on the notes was paid in shares valued at $0.7913 per share. Summit’s stock was trading at distressed levels in December 2022. Duggan received interest payments in shares at $0.7913 — shares that would eventually trade above $33 at peak. That is not incidental compensation. That is a substantial extraction of value from a company he controlled, paid in deeply discounted equity.

Now comes the mechanism the Rainaldi complaint calls self-dealing. Summit announced a Rights Offering in December 2022 — the same month the notes were issued. The Rights Offering ran from February through March 2023 and raised $500 million from shareholders at $1.05 per share. The proceeds were used to repay Duggan’s $400 million note and Zanganeh’s $20 million note. So far, this resembles a straightforward bridge-to-offering structure. Here is where it becomes something else entirely.

Duggan participated in that same Rights Offering — the one whose proceeds repaid his own loan — purchasing 376,489,880 shares for approximately $395.31 million. The net effect of the full cycle: Duggan lent his own company $400 million at 7.5% interest, received repayment from a dilutive offering that all other shareholders funded, and simultaneously used the repayment proceeds to acquire 376 million shares at $1.05 each. Those shares were worth over $33 at the stock’s subsequent peak — a position representing billions in paper gains, acquired at $1.05, funded in part by the repayment of his own bridge loan, financed by shareholder dilution.

Every other Summit shareholder participated in the Rights Offering at $1.05 per share. Every other Summit shareholder bore the dilution of 476 million new shares entering the float. The largest single beneficiary of that dilution was the man who structured the bridge loan in the first place.

The $100 million note tells a second act. Rather than repaying it from the Rights Offering proceeds, Duggan extended it — the proxy frames this as being “in the interest of minimizing shareholder dilution.” The extension ran until September and October 2024. The $75.5 million tranche was repaid through a September 2024 private placement in which Duggan purchased shares at $22.70 each — another below-market acquisition opportunity created by the note extension. The remaining $24.5 million was repaid in cash on October 1, 2024, along with $7.3 million in accrued interest — interest paid by Summit to its own controlling shareholder and co-CEO on a note he had extended at his own discretion.

To summarize the full cycle as the Rainaldi complaint sees it: Duggan lent money to his own company at punishing interest rates. He received interest payments in discounted shares. He was repaid with proceeds from a shareholder rights offering in which he simultaneously acquired a massive new equity position at $1.05 per share. He extended the remaining note to create a second below-market share acquisition opportunity. And he collected $7.3 million in accrued interest from a company he controlled before repayment was finally completed in October 2024.

This is not alleged conduct. This is disclosed conduct — every number above appears in Summit’s own proxy statement filed with the SEC. The Rainaldi complaint does not dispute the facts. It argues that the structure constitutes self-dealing that the Delaware Court of Chancery has equitable jurisdiction to remedy — and that Delaware Senate Bill 21 was passed specifically to retroactively eliminate that remedy for transactions exactly like this one.

Bob Duggan and Maky Zanganeh believe the plaintiff’s allegations are without merit and have stated their intention to vigorously defend against the claims. The Delaware Supreme Court will ultimately determine whether SB 21’s Safe Harbor and Retroactivity provisions are constitutional. If they are not, the full weight of the Court of Chancery’s equitable jurisdiction falls on the transaction structure described above — in the company’s own words, in its own SEC filing.

V. Transferring Risk to Investors

There is one more dimension to the Akeso transaction that has received no attention in the financial press covering the Summit Therapeutics litigation, and it deserves to be stated plainly. The drug at the center of everything — ivonescimab, the asset on which Duggan staked $500 million of bridge financing, engineered a shareholder rights offering to repay himself, and built Summit’s entire $12 billion market capitalization narrative — was licensed from Akeso Inc., a Cayman Islands entity whose beneficial ownership chain does not end in the Cayman Islands.

The chain  runs through CTTQ-Akeso Biomed, through Chia Tai Tianqing Pharmaceutical, through Sino Biopharmaceutical Limited, and ultimately through the Charoen Pokphand Group — Thailand’s largest private company, with over 200 businesses in Mainland China and $82 billion in 2022 revenues — to an ownership structure that is, by the nature of doing business in the People’s Republic of China, subject to the influence and direction of the Chinese Communist Party. We documented this ownership chain in full in our November 2023 article, two years before the Delaware Chancery litigation reached the public record.

This matters for the current litigation in a specific way. The J&J trade secret lawsuit, the Pomerantz shareholder fraud investigation, and the Rainaldi self-dealing complaint all rest on the assumption that ivonescimab has durable commercial value — that the FDA will approve it, that it will achieve meaningful U.S. market penetration, and that the $500 million Duggan paid for the rights will be validated by commercial success.

Every one of those assumptions is subject to a geopolitical risk that none of the litigants has yet raised: in the current U.S.-China trade environment, with tariffs escalating and technology transfer restrictions tightening, the regulatory and commercial status of a drug whose underlying rights flow from a Chinese Communist Party-adjacent ownership structure is not guaranteed. If that geopolitical dimension becomes a material regulatory concern — and it is not an idle one — the commercial narrative that currently underpins Summit’s $12 billion market cap faces a challenge that no clinical trial result can resolve.

Bob Duggan paid $500 million for the rights to a Chinese drug, financed the payment by lending his own company the money, and recovered that loan from his own shareholders through a rights offering in which the prospectus stated explicitly — in bold, in an SEC filing — that the net proceeds would be used for “the repayment to Robert W. Duggan…and Dr. Mahkam Zanganeh…of certain unsecured promissory notes totaling $420 million.” He then participated in that same offering to acquire 376 million shares at $1.05. Summit’s shareholders were told in writing that they were being asked to buy stock specifically to repay the CEO who sold it to them. This transaction is in Summit Therapeutics SEC filing: 

Pursuant to the December 2022 Notes, the Company obtained $520 million in bridge financing through three unsecured promissory notes: (1) a $400 million note issued to Mr. Duggan due on February 15, 2023; (2) a $20 million note issued to Dr. Zanganeh due on February 15, 2023; and (3) a $100 million note issued to Mr. Duggan due on September 15, 2023 (the “$100 Million Note”). The notes had an interest rate of 7.5% through February 15, 2023, with prepaid interest through that date paid in shares valued at $0.7913 per share. For periods after February 15, 2023, interest would accrue at the US prime interest rate plus 50 basis points for three months, and thereafter at the US prime rate plus 300 basis points. The notes contained no warrant coverage and no security interests.

The Company announced the 2023 Rights Offering on December 6, 2022, which ran from February 7 through March 1, 2023. The 2023 Rights Offering was fully subscribed, with stockholders purchasing 476,190,471 shares of the Company’s common stock at $1.05 per share, raising $500 million in gross proceeds.

Mr. Duggan and Dr. Zanganeh fully subscribed to their basic subscription rights, with Mr. Duggan participating by purchasing 376,489,880 shares for approximately $395.31 million.

Following the Company’s fully subscribed $500 million 2023 Rights Offering, Dr. Zanganeh’s $20 million note was repaid on February 15, 2023, and Mr. Duggan’s $400 million note was repaid.

In the interest of minimizing shareholders dilution, the $100 Million Note was extended, and eventually $ 75.5 million repayment was funded through the proceeds of the September 2024 Private Placement in which Mr. Duggan purchased 3,325,991 shares for an aggregate purchase price of $75.5 million as a participant in the September 2024 Private Placement at a purchase price of $22.70 per share, and the remaining $24.5 million was repaid in full on October 1, 2024, along with $7.3 million in accrued interest.

Defendants’ motion to dismiss the complaint is due to be filed on May 16, 2025. Defendants believe that Plaintiff’s allegations are without merit and plan to vigorously defend against its claims.

 According to Forbes, Duggan has donated more than $360 million to the Church of Scientology over his lifetime — money that flowed from the same financial engineering that the Rainaldi complaint now characterizes as self-dealing. David Miscavige presented Bob and Trish Duggan with an IAS trophy for their donations. The Delaware Court of Chancery is now examining whether those donations were built on a foundation of shareholder money extracted through a structure a plaintiff’s complaint calls “plainly usurious.”

VI. The Maky Zanganeh Dimension

Bob Duggan’s co-CEO Maky Zanganeh is the dimension of this story that receives the least public attention and deserves considerably more. 

Zanganeh, an Iranian-born biopharmaceutical executive, was profiled by Forbes in June 2025 in a piece titled “The Unlikely Path from Iranian Revolution to Billionaire Biotech CEO.” She and Duggan are married. She serves as President and co-CEO of Summit. She is named alongside Duggan in the Delaware Chancery self-dealing lawsuit as a beneficiary of the $520 million bridge loan transaction.

Zanganeh’s profile at Summit is that of the scientific and operational architect — the person who evaluates the drug pipeline, manages the Akeso relationship, and runs the day-to-day clinical operations while Duggan provides the capital and the investor narrative. That division of labor makes her the person most directly responsible for what Summit communicated to investors about ivonescimab’s clinical profile before the May and September 2025 stock crashes.

In the shareholder fraud investigation, the question of what management knew and when they knew it runs directly through Zanganeh’s role as the clinical and operational lead. The sequential disclosure pattern — positive efficacy signals, then the May overall survival miss, then the September geographic variation data — raises a specific question about whether the geographic weakness in Western patient populations was known or knowable before the September announcement, and whether that information should have been disclosed earlier.

The Forbes profile and the Delaware Chancery complaint exist in sharp tension. One presents Zanganeh as a pioneering Iranian-American executive building a cancer drug empire. The other alleges she used her control over a public company to extract $114 million through a self-dealing loan. The litigation will determine which narrative reflects the documented financial record.

VII. What the FDA Decision Means for Everything Else

The FDA’s PDUFA goal date of November 14, 2026 is the fulcrum on which every other element of this story balances. 

Summit holds $713 million in cash as of December 31, 2025, and posted a net loss of $1.08 billion for 2025. The company has no revenue. It is entirely dependent on ivonescimab receiving FDA approval and achieving commercial success in the U.S. market — a market where J&J’s Rybrevant and Lazcluze are already established and where the stolen trade secrets allegedly include J&J’s brand strategies and clinical trial materials for exactly those competing drugs.

The BLA is based on HARMONi’s overall results — the same results that showed a 48% progression-free survival benefit but failed to achieve statistically significant overall survival. The FDA may approve on the PFS data. It may require additional overall survival data. It may issue a complete response letter requesting more evidence. The agency plans a complete review with mid-cycle and wrap-up meetings — a standard but thorough process.

If the FDA approves ivonescimab in November 2026, Duggan’s track record narrative — the man who found lightning twice, first with Pharmacyclics, now with ivonescimab — becomes the dominant story. The litigation becomes manageable legal overhead on a commercially successful drug. The stock recovers. The shareholder fraud theory weakens because the drug worked.

If the FDA rejects ivonescimab, the entire enterprise value of Summit collapses. The stock, trading around $16 with 27.4% short interest, would face catastrophic selling. The $713 million cash position becomes the liquidation story rather than the operating runway. The shareholder fraud theory strengthens immeasurably. And the Delaware Chancery self-dealing case becomes a far more dangerous litigation environment for Duggan and Zanganeh personally, because the $114 million they allegedly extracted from the company will have come out of an entity that is now heading toward wind-down.

The J&J trade secret lawsuit adds a third scenario: even if the FDA approves, the commercial launch of ivonescimab may be shadowed by litigation alleging that Summit’s commercial strategy was built in part on stolen J&J competitive intelligence. That is a fact pattern that J&J’s lawyers will develop carefully and that could affect ivonescimab’s commercial trajectory regardless of the FDA outcome.

VIII. What to Watch

The J&J lawsuit’s discovery process. The specific documents allegedly stolen — brand strategies and clinical trial materials for Rybrevant and Lazcluze in EGFR-mutated NSCLC — are directly relevant to Summit’s commercial strategy. Discovery will establish whether those documents were accessed or used by Summit personnel. If they were, the lawsuit transforms from a trade secret case against one former employee into a direct challenge to Summit’s competitive intelligence infrastructure.

The Pomerantz investigation’s conversion to a filed complaint. Pomerantz has been issuing investigation alerts continuously since September 2025. When Pomerantz converts an investigation to a filed class action complaint, the litigation enters a materially different phase. The filing will specify the class period, the alleged misstatements, and the damages theory. Given the two-crash sequence and the geographic variation data, the class period and the specific statements management made about ivonescimab’s global efficacy profile will be the core of the complaint.

Any SEC correspondence to Duggan and Zanganeh. We flagged this in our June 2025 article and we flag it again. When the SEC sends a comment letter to Summit’s management about the ivonescimab disclosures or the self-dealing loan transaction, that letter — and the response — will be the evidentiary record that plaintiff’s attorneys will use. Watch EDGAR for any SEC comment letter filings. The Pino v. Cardone precedent, established by the Ninth Circuit in June 2025, makes the response to any SEC comment letter on Summit’s disclosures potentially as significant as Cardone’s eleven-word response was in that case.

The Delaware Chancery proceedings. The self-dealing lawsuit is in document-production phase. The financial records of the $520 million Akeso bridge loan — including the internal communications between Duggan, Zanganeh, and Summit’s board — will become part of the discoverable record. If those communications show that the loan terms were designed to benefit the insiders rather than the company, the case against Duggan and Zanganeh personally becomes substantially stronger.

The November 14, 2026 FDA decision. This is the single most important event in Summit’s near-term history. Mark the date. Every other thread in this story runs through it.

IX. The Bottom Line

Bob Duggan is eighty years old. He made $3.2 billion from Pharmacyclics. He paid $500 million for the rights to ivonescimab from a Chinese company. He donated 100,000 AbbVie shares to David Miscavige’s IAS. He appears in the Panama Papers alongside Ali Shawkat, whose family moved $140 million out of Iraq through channels so murky that even Appleby’s initially refused the money. 

None of that background establishes that the current litigation against Duggan and Summit will succeed. Litigation is not a verdict. Pomerantz’s investigation is not a class action. The Delaware Chancery lawsuit is not a judgment. The J&J complaint names a former employee, not Summit directly. These are legal proceedings in their early stages.

What the three simultaneous legal vectors do establish is that Bob Duggan’s Summit Therapeutics is operating under the most sustained multi-front legal pressure of any publicly traded company in the Scientology financial network’s history — at exactly the moment when the company’s entire commercial and regulatory future hangs on a single FDA decision seven and a half months away.

Covering Scientologists and their money never gets old. It is just like Uber drivers at the airport: as soon as one leaves, another one arrives shortly if not immediately. It was just a few weeks ago that Grant Cardone’s class action was certified by a federal judge. Now a big law firm is deepening its investigation of Bob Duggan. The pattern holds. The scale escalates. The players change. The architecture does not.

Stay tuned.

Sources and Methodology

Primary court filings: Rainaldi Revocable Trust v. Robert W. Duggan, Mahkam Zanganeh, Manmeet Soni, Robert Booth, and Ujwala Mahatme, C.A. No. 2025-0293-MTZ, Court of Chancery, State of Delaware, Motion to Certify Constitutional Questions to the Delaware Supreme Court, filed May 29, 2025 (documenting the $520 million bridge loan self-dealing allegations, the Safe Harbor and Retroactivity constitutional challenges to Delaware Senate Bill 21, and the expanded defendant roster including Summit’s COO/CFO and board members).

Primary SEC filings: Summit Therapeutics Inc., DEF 14A (Definitive Proxy Statement), filed April 29, 2025, SEC EDGAR CIK 1599298 (documenting board composition, 742,660,724 shares outstanding as of April 15, 2025, Duggan’s dual role as Co-CEO and Chairman, and the “Certain Relationships and Related Party Transactions” section disclosing in full the December 2022 Notes, the 2023 Rights Offering, and the $100 Million Note extension and repayment terms including $7.3 million in accrued interest paid to Duggan); Summit Therapeutics Inc., S-3A Registration Statement, filed January 20, 2023, SEC EDGAR CIK 1599298 (Rights Offering prospectus explicitly disclosing repayment to Duggan and Zanganeh as the stated use of proceeds, in bold, in the prospectus summary); Summit Therapeutics Inc., Form 8-K and earnings release, year ended December 31, 2025, filed February 23, 2026 (reporting $713 million cash position, $1.08 billion net loss for 2025, and FDA BLA acceptance with PDUFA goal date of November 14, 2026).

J&J trade secret litigation: Fierce Pharma / Cafepharma reporting on Janssen Global Services v. former employee now at Summit Therapeutics, March 2026 (documenting the 7,000-plus confidential document downloads, the forensic review timeline, and J&J’s characterization of Summit as a “direct competitor” in EGFR-mutated non-small cell lung cancer); Cafepharma URL: https://www.cafepharma.com/content/jj-files-trade-secret-lawsuit-against-former-oncology-employee-linked-summit-therapeutics.

Shareholder fraud investigations: Pomerantz LLP investor alert press releases, multiple issuances September through October 2025 (documenting the HARMONi Phase III overall survival miss on May 30, 2025 causing a 30.5% single-session stock decline, and the September 7, 2025 geographic variation data causing a further 25.15% decline); Levi and Korsinsky, Schall Law Firm, and Portnoy Law Firm investigation announcements (2025); Pomerantz LLP, Petrobras class action settlement background ($3 billion, Lava Jato case).

Delaware Chancery self-dealing litigation: Bloomberg Law reporting on Summit CEO Bob Duggan sued over “outlandish” self-dealing loan, March 24, 2025; Law360 reporting on shareholder suit in Delaware Court of Chancery seeking corporate records related to $520 million Akeso financing arrangement, July 18, 2024.

Current market data: StockTitan SMMT overview (short interest at 27.4% of float, 74.2% year-over-year increase, 12.2 days to cover, stock price approximately $16 as of early March 2026); StocksToTrade reporting on SMMT 13.26% single-session gain, March 25, 2026; StockAnalysis.com SMMT overview; Simply Wall St. reporting on FDA BLA acceptance and PDUFA date, February 14, 2026.

Akeso ownership chain and transaction background: Scientology Money Project, “Scientology Billionaire Bob Duggan Paid a Chinese Pharma Firm $500 Million and Now He Wants the Money Back,” November 16, 2023 (documenting the full Akeso beneficial ownership chain from Cayman Islands incorporation through CTTQ-Akeso, Chia Tai Tianqing Pharmaceutical, Sino Biopharmaceutical, and the Charoen Pokphand Group, and the SEC Rights Offering prospectus disclosing Duggan repayment as stated use of proceeds); Scientology Money Project, “Scientology Billionaire Bob Duggan Bets $500 Million on an Obscure Chinese Pharmaceutical Company,” November 14, 2023.

Scientology network and background: Forbes Magazine, Bob Duggan profile ($360 million lifetime Scientology donations figure); Forbes, “The Unlikely Path from Iranian Revolution to Billionaire Biotech CEO” (Maky Zanganeh profile, June 2025); Scientology Money Project, “Bob Duggan’s Pharma Company Summit Therapeutics Targeted by Powerhouse Securities Law Firm Pomerantz LLP,” June 5, 2025; Scientology Money Project, “Bob Duggan, the Panama Papers, and the Scientology Money Club,” November 2017 (documenting Duggan’s Panama Papers connections alongside Ali Shawkat and Michael Holstein); Scientology Money Project, prior reporting on Reed Slatkin ($593 million Ponzi scheme, 2003 conviction, Slatkin’s acknowledgment that Duggan taught him finance); Scientology Money Project, prior reporting on David Gentile and GPB Capital Holdings ($1.8 billion Ponzi scheme, seven-year federal prison sentence); Scientology Money Project, prior reporting on Grant Cardone and Pino v. Cardone Capital class action certification (March 2026).

GSK and Revolution Medicines collaborations: Summit Therapeutics press releases, January and June 2026 (GSK collaboration evaluating ivonescimab in combination with risvutatug rezetecan; Revolution Medicines collaboration evaluating ivonescimab with RAS(ON) inhibitors).

Note on methodology: All financial figures drawn from SEC filings are sourced directly from the primary documents cited above. All litigation characterizations reflect allegations that defendants dispute and intend to vigorously defend. No finding of liability has been made in any of the proceedings described in this article. The Pomerantz investigation has not yet been converted to a filed class action complaint as of the date of publication. The Delaware Chancery constitutional questions have not yet been certified to or ruled upon by the Delaware Supreme Court. Copyright 2026.

Jeffrey Augustine is an investigative journalist and licensed private investigator based in Los Angeles. He operates the Scientology Money Project (scientologymoneyproject.com) and Augustine Investigative Services

Summit Therapeutics, SEC Schedule 14A Proxy Statement — Details of the alleged self-dealing and usurious loans made by Bob Duggan and Dr. Maky Zanganeh.